Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines

Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx

(2018) Marie-Anne Loriot et al.   BULLETIN DU CANCER

Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase

(2018) Shikshya Shrestha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetic Information in Clinical Guidelines: The European Perspective

(2018) Jesse J. Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity – Ready for clinical practice?

(2016) Didier Meulendijks et al.   CANCER TREATMENT REVIEWS

Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population

(2016) T Elraiyah et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time

(2016) Carin A.T.C. Lunenburg et al.   EUROPEAN JOURNAL OF CANCER

Upfront Genotyping ofDPYD*2Ato Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

(2016) Maarten J. Deenen et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical validity of aDPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines

(2015) Giuseppe Toffoli et al.   INTERNATIONAL JOURNAL OF CANCER

TranslatingDPYDgenotype into DPD phenotype: using theDPYDgene activity score

(2015) Linda M Henricks et al.   PHARMACOGENOMICS

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS

(2014) Dan Rosmarin et al.   GUT

Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

(2013) K E Caudle et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

(2013) M C van Staveren et al.   PHARMACOGENOMICS JOURNAL

Pharmacogenetic tests: the need for a level playing field

(2012) Munir Pirmohamed et al.   NATURE REVIEWS DRUG DISCOVERY

Pharmacogenomics: “Noninferiority” Is Sufficient for Initial Implementation

(2011) R B Altman   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics: From Bench to Byte

(2008) JJ Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS